Concepta PLC - Concepta signs marketing contract in China
February 15 2018 - 6:41AM
ADVFN NewsWire
("Concepta"
or the "Company")
Concepta signs contract in China to
support marketing of myLotus in Chinese
hospitals
Concepta plc (AIM: CPT), the UK healthcare
company and developer of a proprietary product targeted at the
mobile health market with a primary focus on women's fertility, is
pleased to announce that it has signed a marketing agreement with
Wei Yi Bei Lian (Shanghai) Information Technology Co., Ltd ("BB
Link").
BB Link offers free WiFi to waiting rooms in
1,500 maternity hospitals across China. Concepta has developed a
landing page that will be displayed when patients connect to this
WiFi service. The page will give an overview of the myLotus product
and a link to the Concepta website where more in depth information
can be found. Initially, Concepta's landing
page will be launched in a select number of hospitals, and longer
term, the Company will be able to reach hundreds of thousands of
women in a phased rollout, through a highly targeted marketing
channel.
Concepta's distributors will also train the
doctors at these hospitals on the myLotus product, enabling them to
provide further detailed information and recommendations to
patients that could benefit from its use.
Erik Henau, CEO
says: "Co-operation with BB Link
allows us to target the most relevant potential users of myLotus in
a cost-effective way. Additionally, if women are able to read about
the product prior to seeing the doctor, there is a greater scope
for market penetration.
"BB Link has developed a sophisticated platform with metrics
that permit the measurement of campaign success. We will start with
a trial that will help us to refine our key messages to our
consumers and to learn how the information links to the logistics
of the hospital route.
"This is an important step in building our consumer brand in
China and in working with the hospital route to market."
Enquiries:
The Company
Erik Henau
CEO
Tel: +44 (0) 1234 866601
SPARK Advisory Partners Limited
(Nomad)
Neil Baldwin / Mark Brady
Tel: +44 (0)20 368 355
NOVUM Securities Limited (Broker)
Colin Rowbury
+44 (0) 20 7399 9400
Yellow Jersey (Financial PR)
Georgia Colkin / Joe Burgess / Katie
Bairsto
Tel: +44 (0) 776 932 5254
About Concepta Plc:
Concepta plc is an AIM-quoted pioneering UK
healthcare company that has developed a proprietary product,
myLotus, targeted at the personalised mobile health market with a
primary focus on unexplained infertility* in women.
myLotus is currently the only consumer product
which allows both quantitative and qualitative measurements of a
woman's personal LH**and hCG***hormone levels in a home test,
facilitating higher conception rates and early diagnosis of issues
with fertility hormones. The proposition of myLotus is to help
women conceive naturally.
Concepta has made significant progress recently,
establishing agreements with a number of distributors in China
where myLotus has been given cFDA approval. Concepta is initially
targeting the traditional route to market in China through Chinese
hospitals and plans to add the direct-to-consumer route in the near
future.
The Company is also well on its way to achieving
CE-marking and commencing its direct-to-consumer launch in the UK
and Europe in H1 2018. The Company has identified a significant
global market opportunity, with revenue potential of the Chinese
and EU unexplained infertility market estimated to be worth c.£600m
per annum.
*Unexplained infertility refers to women that
have been unable to conceive after 6 months of trying. This highly
motivated target group of consumers won't typically be offered
medical intervention until 12 months of unsuccessfully trying, with
IVF not offered until two years. Research indicates couples start
to take positive action ahead of this time and there is little
medical support to help them do so.
** LH: Luteinising hormone is produced
by the pituitary gland and is one of the main hormones that control
the reproductive system.
*** hCG: Human chorionic gonadotropin
is a hormone produced by the placenta after implantation and is an
indicator of pregnancy.
About RNS Reach announcements
RNS Reach is an investor communication service
aimed at assisting listed and unlisted (including AIM quoted)
companies to distribute media only / non-regulatory news releases
such as marketing messages, corporate and product information into
the public domain. An RNS Regulatory announcement is required to be
notified under the AIM Rules for Companies.
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Apr 2024 to May 2024
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From May 2023 to May 2024